I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The *LMNA* gene, located on chromosome 1q21.1--21.3, encodes lamin A and C, which are nuclear envelope intermediate filament proteins found on the inner nuclear membrane. These proteins play an important role in many cellular processes, such as in providing a nuclear scaffold for protein complexes, maintaining nuclear structure, regulating gene expression, and playing roles in signaling pathways.\[[@ref1][@ref2][@ref3][@ref4]\] Mutations in the *LMNA* gene cause a series of rare diseases known as laminopathies, which involve skeletal muscles, cardiac muscles, peripheral nerves and fat tissue.\[[@ref5][@ref6]\] Skeletal muscle disorders caused by mutations in the *LMNA* gene can manifest as diverse phenotypes, such as *LMNA*-associated congenital muscular dystrophy (L-CMD), Emery-Dreifuss muscular dystrophy (EDMD), and limb-girdle muscular dystrophy type 1B (LGMD1B).

EDMD was the first described myopathic phenotype of laminopathies. This disorder is characterized by weakness in a scapulo-humero-peroneal distribution; prominent contractures of the ankle, elbow, and spine; and heart issues. The cardiomyopathy and conduction defects may result in a high risk of cardiac sudden death.\[[@ref7][@ref8][@ref9]\] LGMD1B is characterized by predominant scapular and pelvic girdle muscle involvement, and the onset age is later than that of EDMD. Joint contractures and restrictive neck flexions are not prominent in the early stage of the disease, in contrast to EDMD.\[[@ref10][@ref11]\] L-CMD is described in patients whose symptoms manifest in the first few months of life or even during the prenatal period.\[[@ref12][@ref13]\] Patients with L-CMD have delayed motor development, hypotonia, and proximal limb and cervical-axial muscle weakness.\[[@ref14]\] In addition, strikingly, some patients present with dropped head syndrome.\[[@ref15]\] Most patients are unable to walk or sit without assistant during childhood, and some even require early respiratory support or die due to cardiac involvement.\[[@ref16][@ref17]\] The pathological diagnosis of L-CMD is difficult because the histological evidence of inflammation in laminopathies makes it difficult to distinguish from juvenile idiopathic inflammatory myopathy.\[[@ref18]\]

As reported in a previous articles, though these clinical features may be determined by the same *LMNA* mutation, it is not easy to distinguish according to the genotype.\[[@ref11][@ref19]\] Muscle imaging has been reported as an important part of the diagnostic workup of myopathies in recent years.\[[@ref20][@ref21][@ref22][@ref23]\] Magnetic resonance imaging (MRI) has excellent soft-tissue contrast and resolution, it is a safe and noninvasive method for studying and evaluating myopathy.\[[@ref20][@ref24][@ref25][@ref26]\] It is, therefore, the method of detection of the changes, such as fatty infiltration into the muscle, that might serve as indications that differential diagnosis or the evaluation of the severity of the disease should be performed. It has been demonstrated that patients have a similar pattern of fatty infiltration regardless of whether their phenotype is EDMD or LGMD1B.\[[@ref26][@ref27][@ref28][@ref29]\] Our objective was to investigate whether there is a consistent pattern of muscle MRI changes in patients with *LMNA* mutations related to EDMD, LGMD1B, and L-CMD. Moreover, we were dedicated to assessing the possibility of MRI scanning in distinguishing L-CMD from idiopathic inflammatory myopathy.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was approved by the Ethics Committee of Peking University First Hospital, and written informed consent was obtained from all patients or their parents.

Patients {#sec2-2}
--------

Twenty-two patients from twenty-one unrelated families with *LMNA* mutations were recruited from the Department of Neurology, Peking University First Hospital, between March 2012 and October 2017. Their clinical data were recorded, including age of onset; presenting features; joint contractures; muscle weakness involving cervical, proximal, and distal upper and lower limbs; and serum creatine kinase (CK) level \[[Table 1](#T1){ref-type="table"}\]. Cardiac function was assessed via electrocardiograph (ECG), Holter or echocardiogram.

###### 

Clinical characteristics of all patients with various clinical subtypes of *LMNA*-related muscular dystrophy

  Patient number/sex/age at last review (year)   Presenting feature/age at onset (year)              Motor function                                  Contractures                                 CK (U/L)   Heart                                          EMG               Muscle biopsy
  ---------------------------------------------- --------------------------------------------------- ----------------------------------------------- -------------------------------------------- ---------- ---------------------------------------------- ----------------- ------------------------------------------------
  1/female/24                                    Limb weakness and gait disorder/10                  Proximal LL weakness                            Left ankle                                   223        Normal                                         Myogenic change   Myodystrophic change
  2/male/19                                      Limb weakness and myopathic gait/1                  Proximal UL and LL weakness                     Both sides of elbow and ankle                929        Normal                                         Myogenic change   Myodystrophic change
  3/female/29                                    Limb weakness/3                                     Proximal and distal LL weakness                 Both sides of elbow and wrist, rigid spine   902        Atrioventricular junctional escape rhythm      Myogenic change   Myodystrophic change
  4/male/4                                       Limb weakness/2                                     Proximal LL weakness                            Both sides of ankle                          1361       Normal                                         Myogenic change   Myodystrophic change
  5/female/14                                    Limb weakness/4                                     Proximal and distal LL weakness                 Spine, both sides of ankle                   820        Tachycardia, ultrasonic cardiogram is normal   Myogenic change   Myodystrophic change
  6/male/3.5                                     Limb weakness/2                                     Proximal LL weakness                            No                                           215        Normal                                         Myogenic change   Necrotic myopathic change
  7/male/57                                      Limb weakness/56                                    Proximal LL and UL weakness                     No                                           900        Normal                                         Myogenic change   Nonspecific change
  8/female/3 years                               Limb weakness, myopathic gait/1.3                   Proximal LL and UL weakness                     No                                           2623       Normal                                         Myogenic change   Myodystrophic change
  9/male/2.5 years                               Myopathic gait/1                                    LL weakness                                     No                                           413        Normal                                         Myogenic change   Necrotic myopathic change
  10/female/16                                   Limb weakness/11                                    Proximal and distal LL weakness                 No                                           710        Bradycardia                                    Myogenic change   Myodystrophic change
  11/female/3                                    Limb weakness/1                                     Proximal and distal LL weakness                 No                                           350        Normal                                         Myogenic change   Myodystrophic change
  12/female/3                                    Limb weakness/1.2                                   Proximal LL weakness                            Both sides of ankle                          1005       Normal                                         Myogenic change   Myodystrophic change
  13/male/38                                     Limb weakness/5                                     LL and UL weakness                              Both sides of ankle                          800        Normal                                         Myogenic change   Myodystrophic change
  14/male/3                                      Limb weakness/1.2                                   Proximal LL weakness                            No                                           904        Normal                                         Myogenic change   Myodystrophic change
  15/male/6                                      Limb weakness, myopathic gait, hold head poorly/2   Neck, proximal LL and UL weakness               Both sides of ankle                          568        Normal                                         Myogenic change   Myodystrophic change with massive inflammation
  16/male/2.5                                    Motor development delay/0.9                         Neck, proximal LL and UL weakness               Both sides of ankle                          1046       Normal                                         Myogenic change   Myodystrophic change
  17/female/2.3                                  Motor development delay/0.4                         Weakness and hypotonia                          Both sides of ankle                          486        Normal                                         Myogenic change   Myodystrophic change with inflammation
  18/male/1.5                                    Motor development delay, hold head poorly/0.2       Weakness and hypotonia                          Both sides of ankle and wrist                445        Normal                                         Myogenic change   Myodystrophic change with inflammation
  19/female/4.5                                  Motor development delay, hold head poorly/1         Proximal UL and LL weakness; hold head poorly   No                                           673        Normal                                         Myogenic change   End-stage change
  20/female/8                                    Motor development delay/0.7                         Proximal UL and LL weakness; hold head poorly   Both sides of knee and ankle                 372        Normal                                         Myogenic change   Myodystrophic change with inflammation
  21/female/3                                    Motor development delay/0.5                         Weakness and hypotonia, hold head poorly        No                                           898        Sinus arrhythmia                               Myogenic change   Myodystrophic change with inflammation
  22/male/5                                      Motor development delay/1                           Could not stand and walk                        No                                           444        Normal                                         Myogenic change   Myodystrophic change with inflammation

Patient number 13 and number 14 were a father and a son. EMG: Electromyography; CK: Creatine kinase; UL: Upper limbs; LL: Lower limbs.

Muscle pathology {#sec2-3}
----------------

We also analyzed the musculoskeletal system via electromyography and muscle biopsy. All biopsied samples were taken from the biceps brachii or quadriceps. These fresh-frozen muscle specimens were fixed in liquid nitrogen precooled isopentane and were processed for histochemical staining, enzyme histochemical staining, and immunohistochemical staining with first antibodies against major histocompatibility complex 1, complement membrane attack complex, CD3, CD4, CD8, CD20, and CD68.

Genetic test {#sec2-4}
------------

Genomic DNA was extracted from the blood of patients and their parents. For patients No. 2--4, 8, and 15--18, *LMNA* gene mutations were screened via direct sequencing of polymerase chain reaction (PCR) products. All the exons and intron/exons of the *LMNA* gene were PCR-amplified using oligonucleotide primer designed by Primer Premier 5.0 online software (Premier Biosoft International, Palo Alto, CA, USA). For other patients, targeted next-generation sequencing of a panel including muscular dystrophy and congenital myopathy was performed initially, followed by Sanger sequencing of suspicious mutations.

Muscle imaging {#sec2-5}
--------------

MRI examinations were performed on a 3.0T (GE Signa, USA or Philips Achieva, NED) scanner at the level of the thigh in all patients, as previously described.\[[@ref23]\] Lower leg muscle MRI was performed in six patients, including one with EDMD, four with LGMD, and one with L-CMD. Follow-up MRI scans were performed for three patients (patients No. 15, 19, and 22) 1--3 years after the first MRI. The following sequences were used: (1) axial T1-weighted fast spin-echo series for fatty infiltration and (2) axial T2-weighted short-time inversion recovery series with fat suppression series for edema. The parameters used for the MRI sequences were repetition time (TR) = 450--480 ms, echo time (TE) = 20 ms, thickness = 5 mm, section interval = 1 mm, and field of view = 28--32 cm. Two independent observers (Y.Z and H.L), blind to clinical data, quantified the fatty muscle infiltration on the muscle MRI scans using the modified version of the Mercuri score \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].\[[@ref29][@ref30]\]

###### 

Thigh muscle MRI scores of the 21 patients with various clinical subtypes of *LMNA*-related muscular dystrophy

  Patient number/duration of MRI   Diagnosis   Fatty infiltration   Edema                                               
  -------------------------------- ----------- -------------------- ------- --- --- --- --- --- --- --- --- --- --- --- ------
  1/14 years                       EDMD        2                    1       3   4   3   2   1   3   0   2   1   2   4   None
  2/18 years                       EDMD        2                    0       3   3   3   1   2   3   0   1   0   2   2   None
  3/26 years                       EDMD        2                    0       3   4   3   1   1   3   0   2   1   3   4   None
  4/2 years                        EDMD        1                    0       1   1   1   0   2   2   0   2   2   2   0   None
  6/1.5 years                      LGMD        3                    1       4   4   4   1   1   4   1   2   1   4   4   None
  7/1 years                        LGMD        0                    1       2   2   2   3   0   1   3   2   2   1   1   None
  8/1.7 years                      LGMD        2                    0       4   4   4   0   4   4   0   4   2   4   4   None
  9/1.5 years                      LGMD        1                    1       1   1   1   0   0   1   0   1   0   0   0   None
  10/5 years                       LGMD        2                    1       1   1   1   1   1   1   0   1   1   1   0   None
  11/2 years                       LGMD        0                    0       1   1   1   0   0   1   0   0   0   1   0   None
  12/1.8 years                     LGMD        2                    1       1   1   1   1   1   1   1   1   1   1   1   None
  13/33 years                      LGMD        4                    2       3   4   3   2   4   4   2   4   4   4   3   None
  14/1.8 years                     LGMD        2                    0       2   2   2   0   2   2   0   2   1   2   2   None
  15/4 years                       CMD         1                    0       1   1   1   0   1   1   0   0   0   2   2   None
  15/5 years                       CMD         1                    0       3   3   3   0   2   3   0   1   0   1   1   None
  15/8 years                       CMD         1                    0       3   3   3   0   2   3   0   1   0   1   1   None
  16/1.6 years                     CMD         1                    0       1   1   1   0   1   1   0   1   1   1   1   None
  17/2 years                       CMD         3                    0       0   0   0   1   1   1   1   4   4   4   4   None
  18/1.3 years                     CMD         0                    0       0   0   0   0   1   1   1   1   1   1   1   None
  19/3.5 years                     CMD         2                    1       1   1   1   1   3   2   1   2   1   2   1   Mild
  19/5 years                       CMD         2                    1       2   1   1   1   3   2   1   3   2   3   1   None
  20/8 years                       CMD         2                    1       3   2   3   1   4   4   1   4   3   3   2   None
  21/2.5 years                     CMD         2                    0       1   1   1   0   2   3   1   2   2   3   1   Mild
  22/4 years                       CMD         2                    1       2   2   2   1   0   1   0   2   1   2   2   None
  22/5 years                       CMD         2                    3       3   3   3   2   3   3   2   3   2   3   3   None

GM: Gluteus maximus; RF: Rectus femoris; VL: Vastus lateralis; VI: Vastus intermedius; VM: Vastus medialis; SA: Sartorius; AM: Adductor magnus; AL: Adductor longus; GR: Gracilis femoris; SM: Semimembranosus; ST: Semitendinosus; BFL: Long heads of biceps femoris; BFS: Short heads of biceps femoris; EDMD: Emery-Dreifuss muscular dystrophy; LGMD: Limb-girdle muscular dystrophy; CMD: Congenital muscular dystrophy; MRI: Magnetic resonance imaging.

###### 

Lower leg muscle MRI scores of the six patients with various clinical subtypes of *LMNA*-related muscular dystrophy

  Patients number   Diagnosis   Fatty infiltration scores   Edema                                   
  ----------------- ----------- --------------------------- ------- --- --- --- --- --- --- --- --- ------
  5                 EDMD        1                           2       2   2   0   0   0   4   4   1   None
  10                LGMD        1                           1       2   2   1   1   1   3   3   3   None
  11                LGMD        0                           0       0   0   0   0   0   2   2   1   None
  13                LGMD        1                           1       4   3   1   1   1   4   3   3   None
  14                LGMD        0                           0       0   0   0   0   0   1   1   1   None
  19                CMD         0                           0       1   1   0   0   0   2   2   2   None

TA: Tibialis anterior; ED: Extensor digitorum; PB: Peroneus brevis; PL: Peroneus longus; TP: Tibialis posterior; FHL: Flexor hallucis longus; FDL: Flexor digitorum longus; SO: Soleus; MHG: Medial head of the gastrocnemius; LHG: Lateral head of the gastrocnemius; EDMD: Emery-Dreifuss muscular dystrophy; LGMD: Limb-girdle muscular dystrophy; CMD: Congenital muscular dystrophy; MRI: Magnetic resonance imaging.

Statistical analysis {#sec2-6}
--------------------

Data were analyzed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Mann-Whitney *U*-tests were conducted to assess the significance of the differences in the MRI fatty infiltration scores among the three phenotypes. Differences were considered statistically significant at *P* \< 0.05 (two-tailed). Correlations between the summed scores from the MRI findings and clinical assessments (including disease duration and age of onset) and correlations between the summed scores of fatty infiltration and genotypes were analyzed with nonparametric Spearman\'s rank analyses.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Clinical features {#sec2-7}
-----------------

The study included 22 patients (11 males and 11 females) \[[Table 1](#T1){ref-type="table"}\]. The average age at onset was 4.8 ± 11.8 years (0.2--56.0 years). The average disease duration was 2.3 ± 6.8 years (1.0--33.0 years). CK was usually increased, ranging from 223 to 2623 U/L (normal limits: 70--170 U/L); most of the patients (16/22) had less than 5 times the upper limit of CK. The electromyographs showed myogenic changes. The three groups could be distinguished according to their phenotype.

**Group I: Emery-Dreifuss muscular dystrophy**

Patients No. 1--5 belonged to the EDMD group and their ages range from 4.0 to 29.0 years. These patients demonstrated normal developmental motor milestones and presented with slowly progressing muscle weakness, involving both the humeral and peroneal muscles and early onset of knee and elbow contractures. They had difficulties in running, jumping, standing up from a squatting position, or going up and down stairs. Heart function assessed by ECG showed tachycardia in patient No. 5. Holter monitoring of patient No. 3 showed no sinus P-wave or F-wave; atrioventricular junctional escape rhythm; her average heart rate was 46 beats/min; and her echocardiography showed mild tricuspid reflux and pulmonary arterial hypertension. The suggestion of a cardiologist was to implant a pacemaker.

**Group II: Limb-girdle muscular dystrophy type 1B**

Patients No. 6--14 belonged to the LGMD1B group, with ages ranging from 2.5 to 57.0 years. They showed scapular and girdle weakness at the onset of the disease and no evidence of joint contractures until the last interview, except for patients No. 12 and 13. Patient No. 10 had bradycardia, though her echocardiogram was normal. Patient No. 14 was a 3-year-old boy, who was the son of patient No. 13, and had muscle weakness in all his limbs.

**Group III: *LMNA*-associated congenital muscular dystrophy**

Patients No. 15--22 belonged to the L-CMD group, with ages ranging from 1.5 to 8.0 years. They all had abnormal developmental motor milestones and presented with motor development retardation. Most of them could not control their heads or sit or stand unaided. Patient No. 21 had sinus arrhythmia. None of them needed ventilation at the last visit.

Myopathological findings {#sec2-8}
------------------------

The histological findings from the muscle biopsies were not uniform and included muscular dystrophic changes in 18 patients, necrotizing myopathic changes in two patients, a nonspecific change in one patient, and end-stage changes in one patient. Notably, there were six L-CMD patients who showed muscular dystrophic change with multifocal inflammatory cell infiltration in the endomysium or in the perivascular region of the perimysium (patients No. 15, 17, 18, 20, 21, and 22) \[[Figure 1](#F1){ref-type="fig"}\].

![Representative image of the L-CMD patient. Muscle biopsy of L-CMD patient showed myodystrophic changes with massive inflammation (hematoxylin and eosin, original magnification ×400) (a). Bilateral thigh MRI of L-CMD patient showed no sign of edema during the T2-STIR sequence (b). MRI: Magnetic resonance imaging; STIR: Short tau inversion recovery; L-CMD: *LMNA*-associated congenital muscular dystrophy.](CMJ-131-1472-g001){#F1}

Mutation analysis {#sec2-9}
-----------------

The genetic and phenotypic data are summarized in [Supplementary Table 1](#T4){ref-type="table"}. Ten of the heterozygous mutations (c.1357C\>T, c.746G\>A, c.1124C\>G, c.695G\>A, c.1558T\>C, c.745C\>T, c.736G\>A, c.1151A\>G, c.1118T\>A, and c.1580G\>C) had been reported previously, while the other eight were novel mutations (c.754G\>A, c.1152G\>C, c.1681C\>G, c.827G\>C, c.92_94del, c.770T\>C, c.823C\>G, and c.1478A\>C) (according to <http://www.dmd.nl/>, the UMD-*LMNA* database and the HGMD pro-database). None of the mutations were found in their parents or immediate family members, except for patients No. 7, 13 and 14, which indicated that they occurred *de novo*.

###### 

Phenotypes and genotypes of the 22 patients with various clinical subtypes of *LMNA*-related muscular dystrophy

  Patient number   Phenotype   Mutation     LMNA exon/intron   Protein domain      Previously, reported/novel   Inheritance
  ---------------- ----------- ------------ ------------------ ------------------- ---------------------------- -------------
  1                EDMD        c.754G\>A    exon4              Coil region 2       Novel                        *De novo*
  2                EDMD        c.1152G\>C   exon6              Coil region 2       Novel                        *De novo*
  3                EDMD        c.1478A\>C   exon8              Conserved IF-tail   Novel                        *De novo*
  4                EDMD        c.1357C\>T   exon7              Conserved IF-tail   Previously reported          *De novo*
  5                EDMD        c.1357C\>T   exon7              Conserved IF-tail   Previously reported          *De novo*
  6                LGMD        c.746G\>A    exon4              Coil region 2       Previously reported          *De novo*
  7                LGMD        c.1681C\>G   exon10             Linker              Novel                        /
  8                LGMD        c.695G\>A    exon4              Linker              Previously reported          *De novo*
  9                LGMD        c.827G\>C    exon5              Coil region 2       Novel                        *De novo*
  10               LGMD        c.770T\>C    exon4              Coil region 2       Novel                        *De novo*
  11               LGMD        c.823C\>G    exon5              Coil region 2       Novel                        *De novo*
  12               LGMD        c.1357C\>T   exon7              Conserved IF-tail   Previously reported          *De novo*
  13               LGMD        c.1580G\>C   exon9              Conserved IF-tail   Previously reported          /
  14               LGMD        c.1580G\>C   exon9              Conserved IF-tail   Previously reported          Paternal
  15               L-CMD       c.1124C\>G   exon 6             Coil region 2       Previously reported          *De novo*
  16               L-CMD       c.1558T\>C   exon9              Conserved IF-tail   Previously reported          *De novo*
  17               L-CMD       c.1118T\>A   exon6              Coil region 2       Previously reported          *De novo*
  18               L-CMD       c.745C\>T    exon4              Coil region 2       Previously reported          *De novo*
  19               L-CMD       c.92_94del   exon1              Head region         Novel                        *De novo*
  20               L-CMD       c.745C\>T    exon4              Coil region 2       Previously reported          *De novo*
  21               L-CMD       c.1151A\>G   exon6              Coil region 2       Previously reported          *De novo*
  22               L-CMD       c.736G\>A    exon4              Coil region 2       Previously reported          *De novo*

EDMD: Emery-Dreifuss muscular dystrophy; LGMD: Limb-girdle muscular dystrophy; L-CMD: *LMNA*-associated congenital muscular dystrophy; IF: Intermediate filament. \"/\": Not done family genetic analysis.

Muscle magnetic resonance imaging findings {#sec2-10}
------------------------------------------

In total, 21 patients (four with EDMD, nine with LGMD1B, and eight with L-CMD) underwent thigh muscle MRI \[Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}\]. The mean fatty scores varied greatly among the different thigh muscles across the different phenotypes. The results showed that the adductor magnus, the semimembranosus, and the long and short heads of the biceps femoris were the most frequently involved muscles across the three phenotypes, while the gracilis and sartorius were less involved. The involvement of the vasti muscles (vastus lateralis, vastus intermedius, and vastus medialis), while sparing the rectus femoris, was remarkable. Statistically, we did not find any significant differences in the severity of the fatty muscle infiltration between the EDMD and LGMD1B phenotypes.

![Muscle MRI of patients with three different clinical phenotypes caused by *LMNA* gene mutations of bilateral thigh (section on one third part of thigh). (a-d) The most prominently involved muscles of these three phenotypes were the adductor magnus (AM), the semimembranosus (SM), and the long and short heads of the biceps femoris (BF). The gracilis (GR) and sartorius (SA) exhibited less infiltration. The involvement of the vasti muscles (VM), with a relative sparing of the rectus femoris (RF), is prone to be observed in EDMD, LGMD, and advanced-stage CMD; (e and f): Follow-up MRI of CMD patient. MRI: Magnetic resonance imaging; EDMD: Emery-Dreifuss muscular dystrophy; LGMD: Limb-girdle muscular dystrophy; CMD: Congenital muscular dystrophy.](CMJ-131-1472-g002){#F2}

In the L-CMD patients, the results revealed that the adductor magnus, the semimembranosus, and the long and short heads of the biceps femoris were the most frequently involved muscles, while the gracilis and sartorius were less involved. Unlike EDMD and LGMD, we found infiltration of the vasti muscles in the early-stage L-CMD phenotype to a lesser degree \[Figures [1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. This difference was significantly different (vastus lateralis: *Z* = −2.691, *P* = 0.007; vastus intermedius: *Z* = −2.520, *P* = 0.014; and vastus medialis: *Z* = −2.579, *P* = 0.011). However, in our follow-up research of some CMD patients, we observed fatty infiltration in the vasti muscle, with relative sparing of the rectus femoris during the course of the disease progression. The MRI demonstrated a pattern in which advanced-stage L-CMD presented in a similar manner as EDMD or LGMD. Hence, we speculated that the fatty infiltration scores of the vasti muscles were correlated with disease duration. The correlation between the mean score of the fatty infiltration of the vasti muscles and duration was analyzed with nonparametric Spearman\'s rank analyses. A significant difference was detected between the disease duration and mean scores of fatty infiltrations of the vasti muscles (*r* = 0.444, *P* = 0.026,). We used the linear regression method to determine the linear equation of the score of the vasti muscles and disease duration; the result revealed that the muscle score of the vasti muscle as (Y) = 1.483 + 0.075 × disease duration (X) \[[Figure 4](#F4){ref-type="fig"}\].

![Mean scores of the fatty infiltration in individual thigh muscles. GM: Gluteus maximus; RF: Rectus femoris; VL: Vastus lateralis; VI: Vastus intermedius; VM: Vastus medialis; SA: Sartorius; AM: Adductor magnus; AL: Adductor longus; GR: Gracilis femoris; SM: Semimembranosus; ST: Semitendinosus; BFL: Long heads of the biceps femoris; BFS: Short heads of the biceps femoris.](CMJ-131-1472-g003){#F3}

![Correlation between the disease duration and mean scores of fatty infiltration in the vasti muscles (except the rectus femoris): the mean score of the fatty infiltration correlated positively with disease duration (*n* = 25; *r* = 0.444, *P* = 0.026).](CMJ-131-1472-g004){#F4}

Of the six patients who exhibited massive inflammatory cell infiltration in their muscle biopsies, only one patients had a mild edema-like condition in the thigh \[[Figure 1](#F1){ref-type="fig"}\].

There were only six patients who underwent lower leg muscle MRI, including one with EDMD, four with LGMD1B, and one with L-CMD. We found that the soleus and the gastrocnemius medialis and lateralis were the muscles with the most severe fatty infiltration \[[Figure 5](#F5){ref-type="fig"}\].

![Muscle MRI of patients with three different clinical phenotypes caused by *LMNA* gene mutations in the leg area. MRI: Magnetic resonance imaging. EDMD: Emery-Dreifuss muscular dystrophy; LGMD: Limb-girdle muscular dystrophy ; L-CMD: LMNA-associated congenital muscular dystrophy.](CMJ-131-1472-g005){#F5}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The present study contained different phenotypes of laminopathies.\[[@ref31]\] The muscular dystrophies are a large group of genetic muscle disorders.\[[@ref14][@ref27][@ref30]\] In general, different conditions often share similar clinical and histopathological phenotypes, so they are difficult to diagnose. The reliable method involves gene sequencing, but this method is expensive and time consuming. In recent years, there has been a great deal of encouraging data regarding the possible role of muscle imaging in identifying different muscular dystrophies. Some reported articles demonstrated a way to identify specific patterns in some muscular dystrophies, such as Ullrich congenital muscular dystrophy,\[[@ref28][@ref32]\] Duchenne muscular dystrophy,\[[@ref33][@ref34][@ref37]\] and other congenital muscular dystrophies.\[[@ref34]\] This study provided additional useful information regarding the differential diagnosis of laminopathies from other muscle diseases.

The present study showed, via MRI, that patients with *LMNA* gene mutations share a characteristic pattern of muscle involvement. We concluded that the adductor magnus, the semimembranosus, and the long and short heads of the biceps femoris were the most frequently involved muscles across the three phenotypes. The rectus femoris, gracilis, and sartorius either mildly involved or not involved completely. This result was in accordance with previous reports.\[[@ref27][@ref29][@ref35]\] In L-CMD, although the muscle MRI scans showed less fatty infiltration in the vasti muscles in the early stage of the disease, the follow-up MRI revealed fatty infiltration in the vasti muscle, while the rectus femoris was relatively spared, indicating the same muscle involvement pattern as that in EDMD or LGMD1B over the course of disease progression. Some previous researchs have suggested that L-CMD may progress to EDMD or LGMD1B.\[[@ref11][@ref17]\] At the level of the lower leg, we also found that L-CMD, EDMD, and LGMD displayed similar changes. The soleus and the medial and lateral gastrocnemius muscles are the muscles most frequently found to have fatty infiltration. This result was similar to those of other reported imaging studies.\[[@ref26][@ref27]\] The study supported this hypothesis by revealing dynamic muscle MRI changes. L-CMD, EDMD, and LGMD1B are the phenotypes of a continuous entity at different stages; they share the same muscle involvement pattern throughout the disease progression. This information will lead to a way of helping us to further understand this disease and will guide follow-up researches of laminopathies.

Fatty infiltration of the vasti muscles was more frequently found in all phenotypes of the laminopathies, which identified the vasti muscles as a biomarker for evaluating the disease progress. We found that the fatty infiltration score of the vasti muscles is 1.483 + 0.075 × disease duration (X). The infiltration occurred more slowly in patients with DMD, in which the standard deviation of the fatty infiltration scores ranged from 2.41 to 4.87 before 5 years old and from 6.84 to 11.66 between 6 and 10 years old.\[[@ref34]\]

The study provided important clues for differential diagnosis, especially between L-CMD and juvenile inflammatory myopathy. Myopathologically, most of the L-CMD patients in this study displayed massive inflammatory cell infiltration, as observed in the muscle biopsy, which were easily misdiagnosed as inflammatory myopathy. Previous studies also reported histological findings of inflammation in patients with laminopathies, especially in infants and children.\[[@ref18][@ref19][@ref36][@ref37]\] Similar inflammatory changes are not uncommon in other muscular dystrophy diseases including dysferlinopathy, LGMD2I, and facioscapulohumeral muscular dystrophy.\[[@ref38][@ref39][@ref40][@ref41]\] Up to now, the exact mechanism how mutant *LMNA* inducing inflammatory process in skeletal muscle has not been clarified, although one study revealed that nuclear lamina defects can cause the systemic inflammatory response through activating nuclear factor-kappa B signal pathways in HGPS (progeria caused by mutant LMNA) mouse model.\[[@ref42]\] In this study, despite the inflammatory changes on muscle pathology, muscle MRI scans did not show any remarkable muscle edema, as is expected in inflammatory myopathies. Muscle MRI in inflammatory myopathies usually showed comprehensive edema as demonstrated by our previous studies and the others.\[[@ref43][@ref44]\] The follow-up studies using muscle imaging in the study also showed more severe fatty infiltration in L-CMD patients instead of edema changes. The reason for the mismatch between the biopsy and muscle imaging findings remains unknown, but it could imply that MRI would be a useful tool for distinguishing laminopathies from myositis.

In conclusion, the present study shows that patients with laminopathies share similar muscle imaging patterns across different phenotypes. We find that fatty infiltration of the vasti muscles is more frequently found in EDMD and LGMD1B patients compared to L-CMD patients, indicating that the vasti muscles are involved in the advanced stage of the disease. Our results can help guide diagnosis in patients with *LMNA* mutations and will lead the way for further research.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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